<code id='E79DFDB28E'></code><style id='E79DFDB28E'></style>
    • <acronym id='E79DFDB28E'></acronym>
      <center id='E79DFDB28E'><center id='E79DFDB28E'><tfoot id='E79DFDB28E'></tfoot></center><abbr id='E79DFDB28E'><dir id='E79DFDB28E'><tfoot id='E79DFDB28E'></tfoot><noframes id='E79DFDB28E'>

    • <optgroup id='E79DFDB28E'><strike id='E79DFDB28E'><sup id='E79DFDB28E'></sup></strike><code id='E79DFDB28E'></code></optgroup>
        1. <b id='E79DFDB28E'><label id='E79DFDB28E'><select id='E79DFDB28E'><dt id='E79DFDB28E'><span id='E79DFDB28E'></span></dt></select></label></b><u id='E79DFDB28E'></u>
          <i id='E79DFDB28E'><strike id='E79DFDB28E'><tt id='E79DFDB28E'><pre id='E79DFDB28E'></pre></tt></strike></i>

          entertainment

          entertainment

          author:leisure time    Page View:53
          Sammy Kimball for STAT

          Who’s watching the drug price watchmen? Are RSV vaccines too expensive? And is it finally time for Novavax to shine?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Bob Herman joins us to explain his year-long investigation into some brazen conflicts of interest in the world of prescription drug pricing. Then, STAT’s Helen Branswell calls in to walk us through a news-packed week for vaccines, including weighty decisions for Covid-19 and RSV.

          advertisement

          For more on what we cover, here’s the story on conflicts of interest; here’s the latest on RSV vaccines; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          explore

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati
          In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

          CourtesyBristolMyersSquibbBristolMyersSquibbsaidthatitwouldpurchaseMiratiTherapeutics,makerofthecanc

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Bring on the sabbaticals for nurses

          AdobeA newstudy suggeststhatthenursingshortageiseasing,butthatdoesn’tmeanthehealthcaresystemcanstopw